Company profile
GRI Bio, Inc.
NASDAQ:GRIBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06331624 | phase2 | completed | 2024-04-24 | 2025-09-30 | GRI Bio Operations, Inc. | Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF |
| NCT02949375 | phase2 | terminated | 2015-09-01 | 2018-11-01 | GRI Bio Operations, Inc. | Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease |
FDA applications (0)
No records yet.